AbbVie(US:ABBV) Benzinga·2025-11-20 18:01Core Insights - Financial giants are showing a bearish sentiment towards AbbVie, with 33% of traders indicating bearish tendencies compared to 11% bullish [1] - Significant investors are targeting a price range for AbbVie between $100.0 and $260.0 over the past three months [2] - AbbVie has a diverse portfolio in immunology and oncology, bolstered by recent acquisitions [8] Trading Activity - Recent options activity for AbbVie includes 9 unusual trades, with 4 puts valued at $326,123 and 5 calls valued at $230,186 [1] - The largest observed options trades include neutral sentiment for puts and bullish sentiment for certain calls, with notable strike prices [7] Analyst Ratings - Analysts have varying target prices for AbbVie, with an average target of $251.0 and individual targets ranging from $220 to $289 [10][11] - JP Morgan maintains an Overweight rating with a target price of $260, while UBS and Citigroup hold Neutral ratings with targets of $220 and $235 respectively [11] Current Performance - AbbVie’s stock price is currently at $229.06, reflecting a decrease of 1.65% with a trading volume of 1,945,474 [13] - The next earnings report for AbbVie is scheduled in 71 days, and current RSI values indicate a neutral position [13]